Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission

After a pre-NDA meeting, FDA agreed that Cumberland can submit its application for ifetroban in stages, although the evidence package differs from earlier agency suggestions.

16 Nov 2026 · Cumberland Pharmaceuticals Inc CPIX · Company news

Cumberland Pharmaceuticals has said it intends to submit a new drug application to the US Food and Drug Administration for ifetroban, proposed name DYSCORBAN, in cardiomyopathy associated with Duchenne muscular dystrophy. The company made the announcement on 26 October 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Cumberland Pharmaceuticals Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →